Markt für Chemotherapie-induzierte periphere Neuropathie – Erkenntnisse aus globaler und regionaler Analyse – Prognose bis 2031

  • Report Code : TIPRE00028941
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 151
Buy Now

[Forschungsbericht]Der Markt für durch Chemotherapie induzierte periphere Neuropathie soll bis 2028 ein Volumen von 1.174,26 Millionen US-Dollar erreichen, gegenüber 813,48 Millionen US-Dollar im Jahr 2021; es wird erwartet, dass es von 2021 bis 2028 eine CAGR von 5,4 % verzeichnen wird.



Chemotherapie-induzierte periphere Neuropathie ist eine der häufigsten Nebenwirkungen, die durch antineoplastische Mittel verursacht werden. Klinisch handelt es sich um eine meist sensorische Neuropathie, die von motorischen und autonomen Veränderungen unterschiedlicher Intensität und Dauer begleitet sein kann. Aufgrund ihrer hohen Prävalenz bei Krebspatienten stellt die durch Chemotherapie induzierte periphere Neuropathie ein großes Problem sowohl für Krebspatienten und -überlebende als auch für ihre Gesundheitsdienstleister dar, insbesondere weil es derzeit keine einzige wirksame Methode gibt, sie zu verhindern; Darüber hinaus sind die Möglichkeiten zur Behandlung dieses Syndroms begrenzt.



Strategische Erkenntnisse



Der Bericht bietet Einblicke und eingehende Analysen der Markt für chemotherapieinduzierte periphere Neuropathie (CIPN) mit Schwerpunkt auf Markttrends, technologischen Fortschritten und Marktdynamik. Es bietet auch die Wettbewerbslandschaftsanalyse führender Marktteilnehmer auf der ganzen Welt. Darüber hinaus enthält der Bericht die Auswirkungen der COVID-19-Pandemie auf den Markt für durch Chemotherapie induzierte periphere Neuropathie in allen Regionen. Die Pandemie hat weltweit sowohl eine Krise der öffentlichen Gesundheit als auch eine Wirtschaftskrise ausgelöst. Der globale Markt für durch Chemotherapie induzierte periphere Neuropathie wuchs vor der Pandemie aufgrund der Regelmäßigkeit von Krebsvorsorgeuntersuchungen, Konsultationen und Behandlungen ständig. Die erste Welle von COVID-19 störte die Konsultationen, Nachsorgeuntersuchungen und Screenings onkologischer Fälle. Darüber hinaus wirkten sich Unterbrechungen bei klinischen Studien und der Arzneimittelversorgung von Patienten in der Frühphase der COVID-19-Pandemie auf die wichtigsten Bereiche des Marktes für durch Chemotherapie induzierte periphere Neuropathie aus. Eine Verlagerung des Fokus auf die sofortige Behandlung von COVID-19 führte zu Nachlässigkeit gegenüber verschiedenen anderen Erkrankungen. Darüber hinaus behinderte der Rückgang der Erkennung von Krebsfällen und Chemotherapiesitzungen zur Behandlung die Nachfrage nach Diagnosen und Behandlungen von durch Chemotherapie induzierter peripherer Neuropathie.



Lukrative Regionen für den Chemotherapie-induzierten peripheren Neuropathie-Markt



Markteinblicke



Steigende Prävalenz von Krebs Fördert das Wachstum des Marktes für durch Chemotherapie induzierte periphere Neuropathie

Krebs ist weltweit eine der häufigsten Todesursachen. Laut der Weltgesundheitsorganisation (WHO) wurde Krebs im Jahr 2019 in 183 Ländern weltweit als die häufigste Todesursache bei Menschen unter 70 Jahren und in 123 Ländern weltweit als vierthäufigste Todesursache in der Bevölkerung aller Altersgruppen gemeldet . Darüber hinaus verursachten verschiedene Krebsarten laut den von der WHO im März 2021 veröffentlichten Daten im Jahr 2020 ~10 Millionen Todesfälle.



Worlds Most Prevalent Forms of Cancer, 2020

Die zunehmende Prävalenz von Krebs hat die Gesundheitssysteme auf der ganzen Welt belastet und die Nachfrage nach Chemotherapie erhöht. Eine durch Chemotherapie induzierte periphere Neuropathie ist eine häufige Nebenwirkung von neurotoxischen Arzneimitteln gegen Krebs, wie z. und Thalidomid. Die hohe Prävalenz der Chemotherapie-induzierten peripheren Neuropathie gibt Anlass zur Sorge bei Krebspatienten und -überlebenden sowie bei ihren Gesundheitsdienstleistern, insbesondere weil es keinen einzigen wirksamen Weg gibt, um dieser Erkrankung vorzubeugen.



In a Studie, durchgeführt von „The Journal of the International Association for the Study of Pain“ Die Prävalenz chemotherapieinduzierter peripherer Neuropathie wurde mit 68,1 % (57,7-78,4 gemessen im ersten Monat nach der Chemotherapie), 60,0 % (36,4-81,6) im dritten Monat und 30,0 % (6,4-53,5) im sechsten Monat oder später angegeben Die zunehmende Inzidenz chemotherapieinduzierter peripherer Neuropathie mit der zunehmenden Prävalenz von Krebs fördert daher das Wachstum des chemotherapieinduzierten peripheren Neuropathie-Marktes.



Drug Class-Based Insights

h3>

Basierend auf der Medikamentenklasse ist der Markt für durch Chemotherapie induzierte periphere Neuropathie in Steroide, Antidepressiva, Antiepileptika und Betäubungsmittel unterteilt. Im Jahr 2021 hielt das Segment der Steroide den größten Marktanteil. Es wird erwartet, dass das Anti-Anfalls-Segment im Prognosezeitraum die schnellste CAGR von 6,2 % verzeichnen wird.



Markt für durch Chemotherapie induzierte periphere Neuropathie, nach Produkt - 2020 und 2028

< TIP>

Vertriebskanalbasierte Einblicke



Basierend auf dem Vertriebskanal ist der Markt für durch Chemotherapie induzierte periphere Neuropathie in Krankenhausapotheke, Einzelhandelsapotheke und Online-Apotheke unterteilt. Im Jahr 2021 hatte das Segment Krankenhausapotheke den größten Marktanteil. Darüber hinaus wird erwartet, dass das Segment der Einzelhandelsapotheken im Zeitraum 2021-2028 die höchste CAGR von 5,9 % aufweisen wird.



Die Marktteilnehmer durch chemotherapieinduzierte periphere Neuropathie (CIPN) konzentrieren sich auf die Einführung organischer Strategien wie z als Produkteinführung und -erweiterung, um ihre Präsenz und ihr Produktportfolio weltweit zu erweitern und den wachsenden Anforderungen gerecht zu werden.



Nach Geografie



Basierend auf der Geographie ist der Markt für durch Chemotherapie induzierte periphere Neuropathie in Nordamerika (USA, Kanada und Mexiko), Europa (Großbritannien, Deutschland, Frankreich, Italien, Spanien und das übrige Europa), den asiatisch-pazifischen Raum (China, Japan, Indien, Australien, Südkorea und der Rest des asiatisch-pazifischen Raums), der Nahe Osten und Afrika (VAE, Saudi-Arabien, Südafrika und der Rest des Nahen Ostens und Afrikas) sowie Süd- und Mittelamerika (Brasilien, Argentinien und der Rest von Süd- und Mittelamerika).



Unternehmensprofile




  1. Regenacy Pharmaceuticals, Inc.
  2. < TIP>
  3. Asahi Kasei Pharma Corporation

  4. Novaremed

  5. Makscientific, Llc

  6. Wex Pharmaceuticals Inc.

  7. Sova Pharmaceuticals, Inc.

  8. Kineta, Inc.

  9. Aptinyx Inc.

  10. Apexian Pharmaceuticals, Inc.

  11. Winsantor, Inc.



Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is the chemotherapy induced peripheral neuropathy market?

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents. Clinically, CIPN is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration. Due to its high prevalence among cancer patients, CIPN constitutes a major problem for both cancer patients and survivors as well as for their health care providers, especially because, at the moment, there is no single effective method of preventing CIPN; moreover, the possibilities of treating this syndrome are very limited.

What are the driving factors for the chemotherapy induced peripheral neuropathy market across the country?

The factors that are driving and restraining factors that will affect the chemotherapy induced peripheral neuropathy market in the coming years. Major factors driving the market growth include the increasing prevalence of cancer and increasing preference for chemotherapy. Additionally, the growing clinical trials for chemotherapeutic drugs is likely to emerge as a significant future trend in the market during the forecast period. However, lack of consolidated guidelines for chemotherapy hamper the chemotherapy induced peripheral neuropathy market growth.

Which segment is dominating the chemotherapy induced peripheral neuropathy market?

The chemotherapy induced peripheral neuropathy market, by drug class, is bifurcated into steroids, antidepressants, anti-seizure medicines, and narcotics. In 2021, the steroids segment held the largest share of the market. The anti-seizure medicines segment of the chemotherapy induced peripheral neuropathy market is expected to witness growth in its demand at the fastest CAGR during the forecast period.

Who are the major players in market the chemotherapy induced peripheral neuropathy market?

The chemotherapy induced peripheral neuropathy market majorly consists of the players such as Regenacy Pharmaceuticals, Inc, Asahi Kasei Pharma Corporation., Novaremed, Makscientific, Llc, Wex Pharmaceuticals Inc., Sova Pharmaceuticals, Inc., Kineta, Inc., Aptinyx Inc., Apexian Pharmaceuticals, Inc., and Winsantor, Inc. amongst others.

The List of Companies - Chemotherapy Induced Peripheral Neuropathy Market

  1. REGENACY PHARMACEUTICALS, INC
  2. ASAHI KASEI PHARMA CORPORATION
  3. NOVAREMED
  4. MAKSCIENTIFIC, LLC
  5. WEX PHARMACEUTICALS INC
  6. SOVA PHARMACEUTICALS, INC
  7. KINETA, INC.
  8. APTINYX INC.
  9. APEXIAN PHARMACEUTICALS, INC.
  10. WINSANTOR, INC

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports